Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
59
DYN Quote, Financials, Valuation and Earnings
Last price:
$20.36
Seasonality move
:
-5.63%
Day range:
$20.23 - $20.74
52-week range:
$6.36 - $26.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.20x
Volume:
971K
Avg. volume:
3M
1-year change:
-15.1%
Market cap:
$2.9B
Revenue:
--
EPS (TTM):
-$3.66
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DYN
Dyne Therapeutics, Inc.
|
-- | -$0.85 | -- | -12.68% | $38.88 |
|
DNLI
Denali Therapeutics, Inc.
|
$1M | -$0.76 | 559.6% | -13.28% | $32.21 |
|
KYMR
Kymera Therapeutics, Inc.
|
$23.6M | -$0.78 | 97.82% | -11.27% | $115.64 |
|
MNKD
MannKind Corp.
|
$80.2M | $0.03 | 30.4% | 17.65% | $9.61 |
|
RNA
Avidity Biosciences, Inc.
|
$1.8M | -$1.10 | -33.35% | -57.32% | $74.64 |
|
SRPT
Sarepta Therapeutics, Inc.
|
$337M | -$0.37 | -42.37% | -91.57% | $20.61 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DYN
Dyne Therapeutics, Inc.
|
$20.35 | $38.88 | $2.9B | -- | $0.00 | 0% | -- |
|
DNLI
Denali Therapeutics, Inc.
|
$16.99 | $32.21 | $2.7B | -- | $0.00 | 0% | 6.62x |
|
KYMR
Kymera Therapeutics, Inc.
|
$83.13 | $115.64 | $6B | -- | $0.00 | 0% | 155.81x |
|
MNKD
MannKind Corp.
|
$5.93 | $9.61 | $1.8B | 62.95x | $0.00 | 0% | 5.83x |
|
RNA
Avidity Biosciences, Inc.
|
$72.18 | $74.64 | $10.9B | -- | $0.00 | 0% | 454.19x |
|
SRPT
Sarepta Therapeutics, Inc.
|
$22.32 | $20.61 | $2.3B | 20.50x | $0.00 | 0% | 0.95x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DYN
Dyne Therapeutics, Inc.
|
14.83% | 1.659 | 6.68% | 13.23x |
|
DNLI
Denali Therapeutics, Inc.
|
4.58% | 1.220 | 2.09% | 9.43x |
|
KYMR
Kymera Therapeutics, Inc.
|
8.15% | 2.777 | 2.07% | 7.07x |
|
MNKD
MannKind Corp.
|
124.56% | 0.023 | 13.7% | 2.54x |
|
RNA
Avidity Biosciences, Inc.
|
2.58% | 1.649 | 0.78% | 11.04x |
|
SRPT
Sarepta Therapeutics, Inc.
|
48.64% | -0.307 | 61.92% | 1.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DYN
Dyne Therapeutics, Inc.
|
-$500K | -$113.9M | -59.17% | -64.85% | -- | -$110M |
|
DNLI
Denali Therapeutics, Inc.
|
-$2.9M | -$137.4M | -42.48% | -44.34% | -- | -$105.9M |
|
KYMR
Kymera Therapeutics, Inc.
|
$615K | -$88.7M | -30.33% | -33.29% | -3207.89% | -$27.3M |
|
MNKD
MannKind Corp.
|
$61.9M | $18.8M | 24.75% | -- | 22.86% | $22.4M |
|
RNA
Avidity Biosciences, Inc.
|
$11.4M | -$188.8M | -37.09% | -37.47% | -1513.48% | -$156.9M |
|
SRPT
Sarepta Therapeutics, Inc.
|
$230.1M | -$62.9M | -10.24% | -20.67% | -15.75% | -$55.6M |
Dyne Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns DYN or DNLI?
Denali Therapeutics, Inc. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of --. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat Denali Therapeutics, Inc.'s return on equity of -44.34%.
Company Gross Margin Earnings Per Share Invested Capital DYNDyne Therapeutics, Inc.-- -$0.76 $812.2M DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M -
What do Analysts Say About DYN or DNLI?
Dyne Therapeutics, Inc. has a consensus price target of $38.88, signalling upside risk potential of 91.03%. On the other hand Denali Therapeutics, Inc. has an analysts' consensus of $32.21 which suggests that it could grow by 89.61%. Given that Dyne Therapeutics, Inc. has higher upside potential than Denali Therapeutics, Inc., analysts believe Dyne Therapeutics, Inc. is more attractive than Denali Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DYNDyne Therapeutics, Inc.11 2 0 DNLIDenali Therapeutics, Inc.17 0 0 -
Is DYN or DNLI More Risky?
Dyne Therapeutics, Inc. has a beta of 1.302, which suggesting that the stock is 30.242% more volatile than S&P 500. In comparison Denali Therapeutics, Inc. has a beta of 1.115, suggesting its more volatile than the S&P 500 by 11.475%.
-
Which is a Better Dividend Stock DYN or DNLI?
Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Denali Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. Denali Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DYN or DNLI?
Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than Denali Therapeutics, Inc. quarterly revenues of --. Dyne Therapeutics, Inc.'s net income of -$108M is higher than Denali Therapeutics, Inc.'s net income of -$126.9M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while Denali Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus 6.62x for Denali Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DYNDyne Therapeutics, Inc.-- -- -- -$108M DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M
-
Which has Higher Returns DYN or KYMR?
Kymera Therapeutics, Inc. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of -2973.05%. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat Kymera Therapeutics, Inc.'s return on equity of -33.29%.
Company Gross Margin Earnings Per Share Invested Capital DYNDyne Therapeutics, Inc.-- -$0.76 $812.2M KYMRKymera Therapeutics, Inc.22.25% -$0.94 $1B -
What do Analysts Say About DYN or KYMR?
Dyne Therapeutics, Inc. has a consensus price target of $38.88, signalling upside risk potential of 91.03%. On the other hand Kymera Therapeutics, Inc. has an analysts' consensus of $115.64 which suggests that it could grow by 39.1%. Given that Dyne Therapeutics, Inc. has higher upside potential than Kymera Therapeutics, Inc., analysts believe Dyne Therapeutics, Inc. is more attractive than Kymera Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DYNDyne Therapeutics, Inc.11 2 0 KYMRKymera Therapeutics, Inc.18 0 0 -
Is DYN or KYMR More Risky?
Dyne Therapeutics, Inc. has a beta of 1.302, which suggesting that the stock is 30.242% more volatile than S&P 500. In comparison Kymera Therapeutics, Inc. has a beta of 2.281, suggesting its more volatile than the S&P 500 by 128.135%.
-
Which is a Better Dividend Stock DYN or KYMR?
Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kymera Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. Kymera Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DYN or KYMR?
Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than Kymera Therapeutics, Inc. quarterly revenues of $2.8M. Dyne Therapeutics, Inc.'s net income of -$108M is lower than Kymera Therapeutics, Inc.'s net income of -$82.2M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while Kymera Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus 155.81x for Kymera Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DYNDyne Therapeutics, Inc.-- -- -- -$108M KYMRKymera Therapeutics, Inc.155.81x -- $2.8M -$82.2M
-
Which has Higher Returns DYN or MNKD?
MannKind Corp. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of 9.72%. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DYNDyne Therapeutics, Inc.-- -$0.76 $812.2M MNKDMannKind Corp.75.4% $0.03 $181.4M -
What do Analysts Say About DYN or MNKD?
Dyne Therapeutics, Inc. has a consensus price target of $38.88, signalling upside risk potential of 91.03%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 62.08%. Given that Dyne Therapeutics, Inc. has higher upside potential than MannKind Corp., analysts believe Dyne Therapeutics, Inc. is more attractive than MannKind Corp..
Company Buy Ratings Hold Ratings Sell Ratings DYNDyne Therapeutics, Inc.11 2 0 MNKDMannKind Corp.8 0 0 -
Is DYN or MNKD More Risky?
Dyne Therapeutics, Inc. has a beta of 1.302, which suggesting that the stock is 30.242% more volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.821, suggesting its less volatile than the S&P 500 by 17.928%.
-
Which is a Better Dividend Stock DYN or MNKD?
Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DYN or MNKD?
Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Dyne Therapeutics, Inc.'s net income of -$108M is lower than MannKind Corp.'s net income of $8M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 62.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus 5.83x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DYNDyne Therapeutics, Inc.-- -- -- -$108M MNKDMannKind Corp.5.83x 62.95x $82.1M $8M
-
Which has Higher Returns DYN or RNA?
Avidity Biosciences, Inc. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of -1398.33%. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat Avidity Biosciences, Inc.'s return on equity of -37.47%.
Company Gross Margin Earnings Per Share Invested Capital DYNDyne Therapeutics, Inc.-- -$0.76 $812.2M RNAAvidity Biosciences, Inc.91.54% -$1.27 $1.9B -
What do Analysts Say About DYN or RNA?
Dyne Therapeutics, Inc. has a consensus price target of $38.88, signalling upside risk potential of 91.03%. On the other hand Avidity Biosciences, Inc. has an analysts' consensus of $74.64 which suggests that it could grow by 3.4%. Given that Dyne Therapeutics, Inc. has higher upside potential than Avidity Biosciences, Inc., analysts believe Dyne Therapeutics, Inc. is more attractive than Avidity Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DYNDyne Therapeutics, Inc.11 2 0 RNAAvidity Biosciences, Inc.2 12 0 -
Is DYN or RNA More Risky?
Dyne Therapeutics, Inc. has a beta of 1.302, which suggesting that the stock is 30.242% more volatile than S&P 500. In comparison Avidity Biosciences, Inc. has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.581%.
-
Which is a Better Dividend Stock DYN or RNA?
Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avidity Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. Avidity Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DYN or RNA?
Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than Avidity Biosciences, Inc. quarterly revenues of $12.5M. Dyne Therapeutics, Inc.'s net income of -$108M is higher than Avidity Biosciences, Inc.'s net income of -$174.4M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while Avidity Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus 454.19x for Avidity Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DYNDyne Therapeutics, Inc.-- -- -- -$108M RNAAvidity Biosciences, Inc.454.19x -- $12.5M -$174.4M
-
Which has Higher Returns DYN or SRPT?
Sarepta Therapeutics, Inc. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of -45.06%. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.
Company Gross Margin Earnings Per Share Invested Capital DYNDyne Therapeutics, Inc.-- -$0.76 $812.2M SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B -
What do Analysts Say About DYN or SRPT?
Dyne Therapeutics, Inc. has a consensus price target of $38.88, signalling upside risk potential of 91.03%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $20.61 which suggests that it could fall by -7.67%. Given that Dyne Therapeutics, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Dyne Therapeutics, Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DYNDyne Therapeutics, Inc.11 2 0 SRPTSarepta Therapeutics, Inc.7 14 3 -
Is DYN or SRPT More Risky?
Dyne Therapeutics, Inc. has a beta of 1.302, which suggesting that the stock is 30.242% more volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.348%.
-
Which is a Better Dividend Stock DYN or SRPT?
Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DYN or SRPT?
Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Dyne Therapeutics, Inc.'s net income of -$108M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus 0.95x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DYNDyne Therapeutics, Inc.-- -- -- -$108M SRPTSarepta Therapeutics, Inc.0.95x 20.50x $399.4M -$179.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
